MC
ICPT

Maverick Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Maverick Capital’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,827
Closed -$42K – 657
2021
Q3 		$42K Sell
2,827
-46,273
-94% -$740K ﹤0.01% 619
2021
Q2 		$981K Buy
49,100
+12,133
+33% +$241K 0.01% 301
2021
Q1 		$853K Buy
36,967
+20,725
+128% +$578K 0.01% 293
2020
Q4 		$401K Buy
+16,242
New +$538K 0.01% 400

Other funds holding ICPT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Maverick Capital's ICPT Position: Q4 2021 in Review

Maverick Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2021, closing a stake of 2,827 shares — an estimated $42K sold.

Maverick Capital first reported a position in ICPT in Q4 2020 and held it in 4 quarters. The position peaked at $981K in Q2 2021. 147 funds tracked by Wall St. Rank hold ICPT as of Q4 2021.

  • Maverick Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Maverick Capital sold 2,827 Intercept Pharmaceuticals, Inc. shares in Q4 2021, an estimated $42K.
  • Maverick Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2020 and held it in 4 quarters.
  • Maverick Capital's Intercept Pharmaceuticals, Inc. position peaked at $981K in Q2 2021.
  • 147 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2021.

Based on Maverick Capital's 13F filing for Q4 2021, filed 14 Feb 2022.